IBRX Q3: Anktiva Sales Decline Sequentially, Stock Tumbles 18%

What happened

ImmunityBio reported third-quarter 2026 results with total revenue up 53% year over year, but its lead product Anktiva posted a sequential decline from Q2's $50.7 million, breaking an eight-quarter growth streak and missing the key monitoring threshold set by the prior DeepValue report. The company also reported a wider-than-expected net loss as operating expenses rose, reinforcing concerns that revenue growth is not translating into improved profitability or cash flow. The stock fell 18% on the news, reflecting investor disappointment over the sales trajectory and persistent financial strain. The sequential decline is particularly concerning because it occurs despite the ongoing papillary label expansion review and international launch efforts, suggesting that BCG supply constraints or market saturation may be limiting utilization. Management's prior statements about substantial additional funding needs and high cash burn remain unresolved, adding to the risk profile.

Implication

The Q3 results directly contradict the bull case that Anktiva will continue to grow quarter over quarter, as the product's first sequential decline signals potential plateauing in U.S. adoption or ongoing BCG supply constraints. With the stock still pricing in significant expansion, the risk-reward has deteriorated; the bear scenario probability increases, and the stock could fall toward the $5.00 implied value if revenue stalls. The wider loss and rising expenses confirm that the company is far from self-funding, increasing the likelihood of dilutive financing in the near term. The upcoming papillary PDUFA in January 2027 remains a critical catalyst, but even a positive outcome may not quickly resolve the sales slowdown if the underlying utilization issues persist. Given the broken pattern of sequential growth and the lack of a near-term fix for cost control, we maintain a negative outlook and advise against initiating new long positions at these levels.

Thesis delta

The Q3 sequential decline in Anktiva revenue is a direct thesis breaker as defined in the prior report, which specified that failing to exceed Q2's $50.7 million would weaken the commercial scaling thesis. This shifts the probability weight toward the bear scenario, as the company's revenue growth stalls while expenses keep rising, confirming that the stock's valuation is not supported by fundamentals. The overall thesis moves from 'Potential Sell' to a stronger sell stance, with increased conviction that downside risk outweighs any near-term upside from the papillary decision.